Shots:

• GI to receive up front- milestones- and royalties on sales in China- including mainland China- Hong Kong- Macau- and Taiwan while Simcere will be responsible for all clinical development- regulatory approval and commercialization of the assets in territories
• The focus of the collaboration is to develop monotherapy as well as combination therapy with immune checkpoint inhibitors for multiple cancer indications while jointly enhancing clinical development of cancer therapies
• GI-101 is a novel immune-cytokine bi-specific fusion candidate developed using GI Innovation’s GI-SMART platform targeted to treat solid tumors  

Click here to­ read full press release/ article | Ref: Simcere | Image: Twitter